1.
Eur J Anaesthesiol
; 38(4): 438-441, 2021 04 01.
Article
in English
| MEDLINE | ID: covidwho-1116604
Subject(s)
Anesthesia/adverse effects , Anesthetics, Inhalation/adverse effects , COVID-19 , Diabetes Insipidus, Nephrogenic/chemically induced , Hypnotics and Sedatives/adverse effects , SARS-CoV-2 , Sevoflurane/adverse effects , Anesthetics, Inhalation/administration & dosage , Humans , Hypnotics and Sedatives/administration & dosage , Sevoflurane/administration & dosage
2.
Intensive Care Med
; 46(8): 1563-1566, 2020 Aug.
Article
in English
| MEDLINE | ID: covidwho-614084
ABSTRACT
Hospitals worldwide are experiencing a shortage in essential intravenous sedative medications. This is attributable to high number and high sedative needs of COVID-19 critical care patients with disruption of drug supply chains. Inhaled volatile anesthetic agents are an abundant resource and readily implementable solution for providing ICU sedation. Inhaled volatile agents may also provide important pulmonary benefits for COVID-19 patients with ARDS that could improve gas exchange and reduce time spent on a ventilator. We review the use of volatile agents, and provide a technical overview and algorithm for administering inhaled volatile-based sedation in ICUs.